Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Aim(s): To test the efficacy and safety of YF476 in patients with type 1 GCs.
Materials and methods: Eight patients with CAG and multiple type 1 GCs were entered into an open pilot study of YF476 once daily by mouth for 12 weeks. Patients underwent upper endoscopy and GCs were counted and measured at 0, 6 and 12 weeks after starting YF476. Serum chromogranin A (CgA) was measured at 0, 3, 6, 9 and 12 weeks after starting YF476, and 12 weeks after stopping it.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Reidar Fossmark
To read results and conclusion, please login ...
Further abstracts you may be interested in